Program
Anti-STEAP1 Antibody-drug Conjugate ADRX-0405
Its studies are led by Adcentrx Therapeutics.
Furthest: phase 1, since Nov 26, 20241 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Adcentrx Therapeutics | 11 open or running | phase 1since Nov 26, 2024 | Nov 26, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 26, 2024First study: phase 1 study in Solid TumorsFirst studyNCT06710379 · 68 planned · United States
TargetBeta
STEAP1 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) six transmembrane epithelial antigen of the prostate 1 (STEAP1) ”NCIt, by rule
Other programs on STEAP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| xaluritamigrule | Amgen | phase 3 | 7 |
| Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969 | AbbVie | phase 1 | 1 |
| HLX3902 | Fosun Pharma | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06710379Solid Tumors · United States | 1 | Recruiting | Jul 2026 | 68 |
How it is read
Names in the registry
- “ADRX-0405”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.